68 maintained documents

The documentation commons

This is the part of the site we are most proud of. When a topic keeps being re-asked, the community promotes it: the content moves onto a page with named maintainers, a revision history, a review date, and a backlink to the discussion it came from. Promotions are argued in doc review in public, and a page nobody will maintain does not get promoted.

68Documents

26,731Words

68With a source topic

0Past review date

Practical reference (35)Evidence digest (23)Method note (10)

Document	Words	Updated	Review due
Access notes: Australia Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for Australia. Every claim dated, because this changes constantly.	358	19 Feb 2026	21 Jan 2027
Access notes: Canada Practical referenceFDA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for Canada. Every claim dated, because this changes constantly.	338	24 Aug 2025	8 Jun 2027
Access notes: France Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for France. Every claim dated, because this changes constantly.	347	13 Mar 2026	10 May 2027
Access notes: Germany Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for Germany. Every claim dated, because this changes constantly.	348	3 May 2026	3 Jan 2027
Access notes: Ireland Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for Ireland. Every claim dated, because this changes constantly.	339	31 May 2026	22 Jun 2027
Access notes: Italy Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for Italy. Every claim dated, because this changes constantly.	333	11 Apr 2026	23 Oct 2026
Access notes: Netherlands Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for Netherlands. Every claim dated, because this changes constantly.	343	29 Dec 2025	9 Aug 2026
Access notes: New Zealand Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for New Zealand. Every claim dated, because this changes constantly.	329	3 May 2026	13 Nov 2026
Access notes: Poland Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for Poland. Every claim dated, because this changes constantly.	327	6 Jun 2026	9 May 2027
Access notes: Spain Practical referenceEMA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for Spain. Every claim dated, because this changes constantly.	335	30 Mar 2026	19 Dec 2026
Access notes: United Kingdom Practical referenceNHS personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for United Kingdom. Every claim dated, because this changes constantly.	400	11 Jun 2026	15 Jan 2027
Access notes: United States Practical referenceFDA personal import cost per milligram Regulator, prescription status, reimbursement position and practical access route for United States. Every claim dated, because this changes constantly.	402	13 Jun 2026	2 Mar 2027
Amino acid analysis for peptide content Method noteamino acid analysis data table documentation quality Determining how much peptide is actually present, as distinct from how pure it is.	380	17 Feb 2026	9 Aug 2026
Amylin analogues — reference Practical referenceamylin analogues long read randomised trial Amylin analogues: amylin receptor agonists (class), approximate mass Varies, Varies from hours (pramlintide) to about a week (long-acting analogues) half-life. Identity, evidence base, analytical considerations and limitations.	512	11 May 2026	24 Dec 2026
Bacterial endotoxin testing Method noteendotoxin testing data table documentation quality Quantifying bacterial endotoxin, which is a separate question from chemical purity.	326	19 Jun 2026	26 Feb 2027
BPC-157 — reference Practical referenceBPC-157 long read randomised trial BPC-157: synthetic pentadecapeptide (research use only), approximate mass 1419.5 Da, Short; not well characterised in humans half-life. Identity, evidence base, analytical considerations and limitations.	608	26 Jan 2026	17 Mar 2027
Cagrilintide — reference Practical referencecagrilintide long read randomised trial Cagrilintide: long-acting amylin receptor agonist, approximate mass 3750 Da, 7–8 days half-life. Identity, evidence base, analytical considerations and limitations.	547	21 May 2026	26 Jun 2027
Cagrilintide plus semaglutide phase 2 — trial digest Evidence digestcagrisema randomised trial effect size Cagrilintide plus semaglutide phase 2 (Lancet 2021): Does combining an amylin analogue with a GLP-1 agonist add effect?	301	13 Jun 2026	16 Nov 2026
CagriSema — reference Practical referencecagrisema long read randomised trial CagriSema: fixed combination: cagrilintide plus semaglutide, approximate mass —, Both components approximately weekly half-life. Identity, evidence base, analytical considerations and limitations.	502	4 Jul 2026	6 Oct 2026
CJC-1295 — reference Practical referenceCJC-1295 long read randomised trial CJC-1295: ghrh analogue (research use only), approximate mass 3647.2 Da (without DAC), Minutes without DAC; days with DAC half-life. Identity, evidence base, analytical considerations and limitations.	522	12 Jul 2026	7 Jan 2027
Counter-ion content and its consequences Method notecounter-ion content data table documentation quality Understanding why the same peptide at the same purity can weigh differently.	378	19 Apr 2026	18 Jun 2027
Dulaglutide — reference Practical referencedulaglutide long read randomised trial Dulaglutide: glp-1 receptor agonist (fc fusion), approximate mass 59.7 kDa, 5 days half-life. Identity, evidence base, analytical considerations and limitations.	508	1 Dec 2025	2 Apr 2027
Exenatide — reference Practical referenceexenatide long read randomised trial Exenatide: glp-1 receptor agonist (exendin-4 derived), approximate mass 4186.6 Da, 2.4 h (immediate release) half-life. Identity, evidence base, analytical considerations and limitations.	515	7 Aug 2025	5 Dec 2026
FLOW — trial digest Evidence digestFLOW trial randomised trial effect size FLOW (N Engl J Med 2024): Does semaglutide reduce kidney disease progression and related death?	328	2 Jun 2026	25 Sep 2026
Forced degradation and stability-indicating methods Method noteforced degradation data table documentation quality Demonstrating that a method can separate the compound from the things it turns into.	358	17 May 2025	24 Mar 2027
Growth-hormone-releasing peptides (GHRP class) — reference Practical referenceGHRP class long read randomised trial Growth-hormone-releasing peptides (GHRP class): ghrelin receptor agonists (research use only), approximate mass Varies by member (GHRP-2 817.0 Da; GHRP-6 ≈ 873.0 Da), Minutes to tens of minutes half-life. Identity, evidence base, analytical considerations and limitations.	562	16 Nov 2025	14 Mar 2027
Ipamorelin — reference Practical referenceipamorelin long read randomised trial Ipamorelin: selective growth hormone secretagogue (research use only), approximate mass 711.9 Da, 2 h half-life. Identity, evidence base, analytical considerations and limitations.	514	28 Apr 2025	13 Mar 2027
Janoshik Analytical — what its reports establish Practical referenceJanoshik Analytical third-party testing documentation quality Janoshik Analytical: Chromatographic purity and mass-spectrometric identity on submitted samples. What a report from this service does and does not establish, and how we cite it.	300	23 Apr 2026	22 Aug 2026
LC-MS identity confirmation Method noteLC-MS data table documentation quality Confirming that the species eluting at the main peak has the expected mass.	420	13 Mar 2026	23 Mar 2027
LEADER — trial digest Evidence digestLEADER trial randomised trial effect size LEADER (N Engl J Med 2016): Does liraglutide reduce major adverse cardiovascular events?	296	9 Jul 2026	27 Mar 2027
Liraglutide — reference Practical referenceliraglutide long read randomised trial Liraglutide: glp-1 receptor agonist, approximate mass 3751.2 Da, 13 h half-life. Identity, evidence base, analytical considerations and limitations.	546	25 Jul 2026	8 Mar 2027
Mazdutide — reference Practical referencemazdutide long read randomised trial Mazdutide: dual glp-1 and glucagon receptor agonist, approximate mass —, Suitable for weekly dosing half-life. Identity, evidence base, analytical considerations and limitations.	490	16 Jun 2025	17 Oct 2026
Medutest — what its reports establish Practical referenceMedutest third-party testing documentation quality Medutest: Combined purity and identity reporting. What a report from this service does and does not establish, and how we cite it.	257	25 Feb 2026	28 Feb 2027
Oral semaglutide — reference Practical referenceoral semaglutide long read randomised trial Oral semaglutide: glp-1 receptor agonist, oral formulation, approximate mass 4113.6 Da (same molecule), 1 week half-life. Identity, evidence base, analytical considerations and limitations.	576	17 Oct 2025	24 Jan 2027
Orforglipron — reference Practical referenceorforglipron long read randomised trial Orforglipron: oral non-peptide glp-1 receptor agonist, approximate mass —, Suitable for once-daily oral dosing half-life. Identity, evidence base, analytical considerations and limitations.	529	22 Feb 2026	11 Jun 2027
Orforglipron phase 2 (obesity) — trial digest Evidence digestorforglipron randomised trial effect size Orforglipron phase 2 (obesity) (N Engl J Med 2023): Can an oral non-peptide GLP-1 agonist produce injectable-like weight reduction?	295	24 Sep 2025	4 Apr 2027
Peak integration in practice Method notepeak integration data table documentation quality Understanding how much of a reported purity figure is the sample and how much is the integration.	390	9 May 2026	21 Dec 2026
PeptideMeter — what its reports establish Practical referencePeptideMeter third-party testing documentation quality PeptideMeter: Purity analysis plus structured, dated supplier verification records. What a report from this service does and does not establish, and how we cite it.	263	5 Jul 2026	28 Oct 2026
PIONEER 6 — trial digest Evidence digestPIONEER programme randomised trial effect size PIONEER 6 (N Engl J Med 2019): Is oral semaglutide cardiovascular-safe?	307	8 May 2026	9 Jan 2027
Retatrutide — reference Practical referenceretatrutide long read randomised trial Retatrutide: triple gip, glp-1 and glucagon receptor agonist, approximate mass 4731 Da, 6 days half-life. Identity, evidence base, analytical considerations and limitations.	586	2 Apr 2026	4 Dec 2026

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →